What’s keeping biosimilar drugs from the U.S. market?

Name: What’s keeping biosimilar drugs from the U.S. market?
Uploaded: 2014-04-19T20:39:32Z
Duration: P596S
Description: NewsHour looks at a revolutionary class of drugs called "biologics." Americans have been paying more for their benefits than patients in Europe or Asia some say, because the "generic" versions or "biosimilars" have not hit the U.S. market. Dr. Emily Senay looks into why there's a delay and when American consumers can expect discounts.

Clip: 04/19/2014 | 9m 56s

NewsHour looks at a revolutionary class of drugs called "biologics." Americans have been paying more for their benefits than patients in Europe or Asia some say, because the "generic" versions or "biosimilars" have not hit the U.S. market. Dr. Emily Senay looks into why there's a delay and when American consumers can expect discounts.

Aired: 04/19/14

Rating: NR

Problems Playing Video? | Closed Captioning

Major corporate funding for the PBS NewsHour is provided by BDO, BNSF, Consumer Cellular, American Cruise Lines, and Raymond James. Funding for the PBS NewsHour Weekend is provided by Consumer …

Major corporate funding for the PBS NewsHour is provided by BDO, BNSF, Consumer Cellular, American Cruise Lines, and Raymond James. Funding for the PBS NewsHour Weekend is provided by Consumer Cellular and American Cruise Lines. For a complete list of funders for the PBS NewsHour and PBS NewsHour weekend, click here.

Support provided by:

What’s keeping biosimilar drugs from the U.S. market?

More News and Public Affairs Shows